Drug Trial Radar · NCT01506986
Helicobacter Eradication Aspirin Trial
Last checked: Nov 19, 2026Latest source record: May 17, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30,024
Actual
Start
Mar 2012
Primary completion
Oct 31, 2017
Study completion Mar 16, 2022
Sponsor
- Lead sponsor
- University of NottinghamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Nottingham University Hospitals NHS Trust; University of Southampton; University of Durham; University of Birmingham; University of Oxford; Queen's University, Belfast
- First posted
- Jan 10, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Single group
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
HEAT (Helicobacter Eradication Aspirin Trial) is a large simple double-blind placebo controlled outcomes study of Helicobacter pylori (H. pylori) eradication to prevent ulcer bleeding in aspirin users. It will be run by the University of Nottingham, with recruiting centres across the UK. This trial is funded by the National Institute of Health Research Health Technology Assessment (NIHR HTA) Programme. Aspirin use is widespread and increasing in elderly patients. The main hazard is gastrointestinal bleeding, which may be increasing because of increasing aspirin use. This trial is based on evidence that peptic ulcer bleeding in aspirin users occurs predominantly in H. pylori positive people. Patients will be identified by their GPs, then asked to attend an appointment with a Research Nurse to consent to the trial and take a H. pylori breath test. Those with a positive result will be randomised to receive a one week course of either eradication treatment or placebo. No follow-up visits are required, but instead information will be extracted from the patients' electronic medical record using the MiQuest search tool. The trial will continue until 87 adjudicated events (hospitalisation because of definite or probable peptic ulcer bleeding) have occurred, which would occur after a mean 2.5 patient years of follow-up, if trial assumptions are correct.
Conditions
- Gastrointestinal Ulcer Haemorrhage
- Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Interventions
Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mgDrug
All three medications will be taken orally, twice daily, for seven days.
Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mgDrug
Medication to be taken orally, twice a day, for seven days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The rate of hospitalisation due to peptic ulcer bleeding in patients who enter the randomised study (only the first event per patient will be analysed), adjudicated by a blinded Committee as definite or probable.Time frame: 4 years
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Queen's University
Belfast, United Kingdom
University of Birmingham
Birmingham, United Kingdom
Durham University
Durham, United Kingdom
University of Nottingham
Nottingham, United Kingdom
University of Oxford
Oxford, United Kingdom
University of Southampton
Southampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.